, 19 2. Schémas, doses er volumes d'irradiation

, Dose aux organes à risque (OAR)

C. Modalités-de-chimiothérapie and .. .. ,

.. .. Résultats,

B. Caractéristiques and .. .. ,

C. , Contrôle local, survie sans progression et survie globale

D. Analyse-dosimétrique-d'une-récidive-locale and .. .. ,

E. Toxicités and .. .. ,

F. Toxicités and .. .. ,

. .. V.-conclusion,

. Vi and . .. Références,

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, International journal of cancer, vol.136, issue.5, pp.359-86, 2015.

E. B. Stelow and B. M. Wenig, Update From The 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Nasopharynx. Head and neck pathology

A. W. Lee, W. T. Ng, Y. H. Chan, H. Sze, C. Chan et al., The battle against nasopharyngeal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol.104, pp.272-280, 2012.

R. Simo, M. Robinson, M. Lei, A. Sibtain, and S. Hickey, Nasopharyngeal carcinoma: United Kingdom National Multidisciplinary Guidelines, The Journal of laryngology and otology, vol.130, issue.S2, pp.97-103, 2016.

P. Jardel, J. Thariat, P. Blanchard, F. Elloumi, N. Toumi et al.,

, Bulletin du cancer, vol.101, issue.5, pp.445-54, 2014.

F. C. Ho, I. W. Tham, A. Earnest, K. M. Lee, and J. J. Lu, Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence, BMC cancer, vol.12, p.98, 2012.

S. H. Huang and B. O'sullivan, Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Current treatment options in oncology, vol.18, p.40, 2017.

J. Falck, J. Coates, and S. P. Jackson, Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage, Nature, vol.434, issue.7033, pp.605-616, 2005.

P. Maingon, P. Blanchard, F. Bidault, and L. Calmels, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, vol.20, pp.104-113, 2016.

J. K. Tuan, T. C. Ha, W. S. Ong, T. R. Siow, I. W. Tham et al., Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol.104, pp.305-316, 2012.

C. M. Nutting, J. P. Morden, K. J. Harrington, T. G. Urbano, S. A. Bhide et al., Parotidsparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. The Lancet Oncology, vol.12, pp.127-163, 2011.

M. K. Kam, S. F. Leung, B. Zee, R. M. Chau, J. J. Suen et al., Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients, Journal of clinical oncology : official journal

, American Society of Clinical Oncology, vol.25, issue.31, pp.4873-4882, 2007.

G. Peng, T. Wang, K. Y. Yang, S. Zhang, T. Zhang et al., A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, vol.104, pp.286-93, 2012.

M. Al-sarraf, M. Leblanc, P. G. Giri, K. K. Fu, J. Cooper et al., Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.16, issue.4, pp.1310-1317, 1998.

P. Blanchard, A. Lee, S. Marguet, J. Leclercq, W. T. Ng et al., Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis, The Lancet Oncology, vol.16, issue.6, pp.645-55, 2015.

J. Zhang, H. Peng, L. Chen, W. F. Li, Y. P. Mao et al., Decreased Overall and CancerSpecific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis, Journal of Cancer, vol.8, issue.13, pp.2587-94, 2017.

S. L. Wolden, W. C. Chen, D. G. Pfister, D. H. Kraus, S. L. Berry et al., Intensitymodulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial SloanKettering experience, International journal of radiation oncology, vol.64, issue.1, pp.57-62, 2006.

A. Mazal, J. L. Habrand, S. Delacroix, J. Datchary, R. Dendale et al., Bulletin du cancer, vol.97, issue.7, pp.831-877, 2010.

Z. Taheri-kadkhoda, T. Bjork-eriksson, S. Nill, J. J. Wilkens, U. Oelfke et al., Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons, Radiation oncology, vol.3, p.4, 2008.

G. Noel, Augmentation de dose délivrée dans les cancers du cavum classés T2b, vol.3, p.4

, N0 M0 par une irradiation de photons et de protons. Etude de phase II, Protocole CPO, vol.00, p.1

N. Publié, , 2001.

A. Chan, J. A. Adams, E. Weyman, R. Parambi, T. Goldsmith et al., A Phase II Trial of Proton Radiation Therapy With Chemotherapy for Nasopharyngeal Carcinoma, International Journal of Radiation Oncology ? Biology ? Physics, vol.84, issue.3, pp.151-153, 2012.

G. D. Lewis, E. B. Holliday, E. Kocak-uzel, M. Hernandez, A. S. Garden et al.,

, Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes, Head & neck, vol.38, issue.1, pp.1886-95, 2016.

A. W. Chan, L. J. Liebsch, D. G. Deschler, J. A. Adams, L. V. Vrishali et al., Proton radiotherapy for T4 nasopharyngeal carcinoma, Journal of Clinical Oncology, vol.22, p.5574, 2004.

J. W. Kim, J. H. Cho, K. C. Keum, J. H. Kim, G. E. Kim et al., IMRT with simultaneous integrated boost and concurrent chemotherapy for nasopharyngeal cancer: plan evaluation and treatment outcome, Japanese journal of clinical oncology, vol.42, issue.12, pp.1152-60, 2012.

L. R. Wu, Y. T. Liu, N. Jiang, Y. X. Fan, J. Wen et al., Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: An analysis of 614 patients from a single center, Oral oncology, vol.69, pp.26-32, 2017.

W. Zhang, Y. Chen, L. Chen, X. Liu, Y. Sun et al., Importance of maintaining body weight for prevention of distant metastasis of nasopharyngeal carcinoma: An alternative workflow for cancer-risk assessment, Journal of Cancer, vol.8, issue.12, pp.2269-76, 2017.

E. B. Holliday, . Ga, D. I. Rosenthal, C. D. Fuller, W. H. Morrison et al.,

. Bm, X. R. Zhu, X. Zhang, E. Hanna, B. S. Glisson et al., Proton Therapy Reduces Treatment-Related Toxicities for Patients with Nasopharyngeal Cancer: A Case-Match Control Study of Intensity-Modulated Proton Therapy and Intensity-Modulated Photon Therapy, International Journal of Particle Therapy, vol.2, issue.1, pp.19-28, 2015.

E. Résumé, Introduction : Le but de cette étude était d'évaluer l'efficacité et la tolérance d'une association de protons et de photons dans la prise en charge thérapeutique de patients atteints d'un cancer du nasopharynx localement avancé de stade III-IVa. Matériels et méthodes : De novembre, 1999.

, Tous les patients ont reçu une chimiothérapie concomitante. Le contrôle local, la survie sans récidive et la survie globale ont été déterminés, ainsi que les toxicités aiguës et tardives. Résultats : Les caractéristiques des patients étaient : un âge médian de 49 ans, le sexe masculin pour 71% des cas, 88% des patients étaient stade IVa avec une majorité de T4N0M0 (82%). La médiane de suivi était de 99 mois, IVa ont été traités au centre de protonthérapie d'Orsay. Les aires ganglionnaires cervicales bilatérales étaient traitées par des photons à la dose de 40-54Gy

, Mots-clefs : Radio-chimiothérapie, Protonthérapie, Cancer de la tête

. Efficacy, . Toxicity, . Proton, . Photon-radiation-for, . Locally et al., The aim of this study was to assess the treatment outcome and toxicity for patients with stage III-IVa nasopharyngeal carcinoma (NPC) treated with a combination of proton and photon beams as well as chemotherapy. Materials and methods: Between, vol.70, pp.70-78, 1999.

R. Gy, The primary tumor volume including microscopically extensions received a complementary dose with proton. The end-points of the study were locoregional control, survival, and treatment-related toxicity. Results: Patients characteristics were: median age 49, 71% male, 64% World Health Organization II, 12% Stage III, 88% Stage IVa, with a majority (82%) of T4N0M0. After a median follow-up of 99 months, there were two local relapses and two patients had developed distant metastasis. The 2-, 3-, 5-and 10-year actuarial locoregional free survival and overall survival were 94% and 88%, 94% and 86%, 86% and 74%, and 86% and 66%, respectively, Bilateral lymph node in the neck (I -V levels) received from 40 to 54 Gy with photon beam